Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
InVivo Therapeutics Holdings Corporation focuses on developing innovative therapies for spinal cord injuries, particularly its biopolymer scaffold technology aimed at facilitating nerve regeneration. The company operates primarily in the United States, with its flagship product currently in clinical trials, which positions it uniquely within the niche market of spinal cord injury treatment.
InVivo generates revenue through the commercialization of its proprietary biopolymer scaffolds designed for spinal cord repair. The company benefits from a unique competitive advantage due to its patented technology, which is designed to promote nerve regeneration and potentially improve patient outcomes, thus allowing for premium pricing.
Progress and results from clinical trials for its spinal cord injury products
Regulatory approvals from the FDA for new therapies
Partnerships or collaborations with larger pharmaceutical companies
Changes in reimbursement policies affecting spinal injury treatments
Regulatory changes affecting the approval process for new medical devices
Technological disruption from competing therapies or advancements in spinal injury treatment
Emergence of new competitors with alternative therapies for spinal cord injuries
Potential for larger companies to enter the market with superior resources
High cash burn rate due to ongoing clinical trials and R&D expenses
Limited revenue generation leading to potential liquidity risks
low - The demand for biotechnological innovations in spinal injury treatments is less sensitive to economic cycles compared to other healthcare sectors.
Interest rates affect InVivo's cost of capital for funding R&D and clinical trials, but the impact is minimal given the low debt levels.
minimal - The company has a low debt-to-equity ratio of 0.06, indicating limited reliance on credit.
growth - Investors interested in high-risk, high-reward opportunities in innovative healthcare solutions.
high - The stock has shown significant volatility, with a 1-year return of -70.6% reflecting market uncertainty.